michelcarroll/llama2-earnings-stock-prediction-fine-tune huggingface dataset:
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
This is -- sorry, the revenue initiatives. Ravi, I think most of it is that you would expect -- and Andrew mentioned and he can jump in again, but a new arm system, which ours was 20 years old, and we're excited to have the new one in place. There's a few things. I mean they're just -- we're not super excited to talk about, but distributing our premium economy cabin.
Indirect channels, we only distribute prior and direct channels. The American, oneworld, WCI stuff, those are all sort of on the list of things that are going to contribute. I don't think we want to talk a whole lot about things that are new that we might be looking at or different today. But if we get closer to an investor event, we'll lay out sort of more clarity on all of these areas.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I get it. Okay. So I think what's more important than the physician than the visits to the physician offices is actually our patient, our ARIKAYCE trainers that visit the patients to introduce them to the device, to train them on the device on how to successfully initiate therapy with ARIKAYCE and what to expect from therapy. And so we do see that as the in-person training varies, so we do remote and we do in-person, and the patient is absolutely entitled to choose in which manner they want to receive that training. I think we see slightly better results when we have the in-person training, but the virtual training is also effective in introducing the patient we just see as we're able to get to in-person to spend a significant amount of time with patients in their homes and talking and introducing the therapy that that has a beneficial impact on patients tolerating and continuing on therapy.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thank you. Since IMSS was launched in China, is that made in Taiwan, and is that something that Sinochem and LCY can do as well? Do you think the competition is going to be primarily other materials?

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
So, yes, I will tell you what I'd like to have from these rating agencies is, you know what, they need to start giving one rating, LT, that's it, instead of A, B, C, D, give me a LT rating, that's what the investors want to see. They give them money all the time. Every price starts 200 to 250 basis points below competition all the time, as you know.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I think thats definitely the case. So were coming kind of bouncing off the bottom here. Youre correct that in the third quarter, although NIM expanded, we really didnt get the full benefit of the loans that were brought on in September or even the pool purchase that was in late August, nor we did deploy about $50 million into securities as well. So I think in the fourth quarter, when you have the full quarter impact of that growth, youre going to see expanded margins. The other outlook item is were feeling very bullish about the teams weve brought on board. Theyre doing great building pipelines. Its too early to be able to really fine-tune how productive they may be. But its possible we may be able to deploy all of our excess liquidity as early as midyear next year, which would be one or two quarters earlier than we thought. And that bodes well for margin as well as net interest income.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, it is possible. It's something that's probably going to be somewhat challenging as a single arm with multiple drugs. But once we have all the data put together, we'll definitely have a conversation with the FDA and see what their appetite is for an accelerated approval. We know that accelerated approvals in CLL are challenging these days for them. But we do feel that the data will be quite encouraging. So we'll take our shot. No guarantees for sure, no guarantees, but we'll take our shot. If not, again, we think it's a very robust data set that should provide potential update to the NCCN guidelines.
Our Phase III, we're well into the enrollment phase, and so that'll be ongoing. And both drugs are approved. And obviously, we would not be marketing at all to U2 plus venetoclax. But physicians are capable of making their own decisions. And again, both drugs would be approved in the indications that someone might use them. So, again, we'll at best have something that's useful for [Indecipherable] listing. Best case scenario would be an approval. But the second option would be, it'll be useful for [Indecipherable] listing, and that's pretty good, too. And then like I said, the registration trial is ongoing.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thank you. Good morning. Glen, I noted your comments about the balance sheets with the leverage being the lowest of the peer group. I was just wondering how you're thinking about the leverage over the cycle of the capex plans? Who got C-band options in 18 months? How are you thinking about where that's going to go over the next few quarters and how that plays into the dividend model and the payout ratio for the dividend as well? And if you've had any discussions with the rating agencies since the auction?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thank you. As do I.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
So, we -- I mean, right now we're -- we're working with all of our partners. We -- we generally have long-term deals with both suite holders as well as sponsor agreements. We believe in being very -- we believe in -- in being consumer-friendly. And so, we're working with all of our partners right now.
Obviously, New York is in a different place today than it was a year ago. But I'm hopeful on the rebound. I feel the city getting more lively every single day I'm here. And -- and -- and our partners, you know, we're very focused and staying very close to our partners and thinking long term.
And so, while -- while we're currently focused on this season, it's hard to take a -- a really long-term point of view, but I feel very good about long term and our long-term relationships and the way the partners -- how we've been able to -- both suite holders and partners, how they've been working with us during these difficult times.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I think the impact really is really about duration, right? So you've got the Philips recall, that issue. But then the other manufacturers have chip shortages as well. So there is basically is and going to be somewhat of a shortage of equipment. The other manufacturers combined, even if they had full chips couldn't make up the Philips capacity.
So there's some metering effect here. And the faster the chip shortage gets resolved, at least for that small sector of manufacturing, will really impact whether it's a big, small -- again, we think it's probably larger than zero from an impact, but we don't think it's bigger than what Debbie described.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, Jamere talked about the fact that we're beginning to see some pretty significant inflation on certain product categories. I don't think that that's been a big driver of our performance in Q3, but it is something that we are very mindful of as we move into Q4, and frankly we have in the past some of those cost along [Phonetic] to our customers just like we've done for the last 40 years.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, yeah. That was in the compensation and benefits fine, the $1.8 million save. And that was -- what I tried to profess is that that happened in the fourth quarter. But that's not going to be our run rate going forward.
We do expect that not to be recurring.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks, Noah.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. So again, Colin, how are you? 

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Good morning, Ric. How are you doing? That was a lot of fun.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Good morning, everyone. I guess first question related sort of more clarification I want to understand like when you show these bridges, like you're showing some pretty good incremental margins on supply chain issues, inflationary pressures, etc. That's in the operating performance?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, I think what that speaks to is the fact that secondaries are becoming an increasingly more and more important part of the overall asset class. So the growth in that space overall has been significant. But I would note, and you just said it, they're acquiring. This is not new entrants coming into the market. These are acquiring franchises that are already there and in some cases, we've already had been competing with. So I think the success that we've achieved to date has already been in the landscape where all of those franchises exist and have continued to exist. So I think what that tells you is it's a really big pool of capital that's out there. We have sort of our share of that. We believe that both that pool of capital will continue to grow, and we're hopeful that our share continues to grow. But we don't really see the acquisitions as being all that noteworthy or impactful to the business.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hi. It's Roy for Jason. Thanks for taking my questions, just a couple of quick ones. So for felzartamab and IgAN, just curious what you see as a market opportunity. And then for the trial that's going to start later, any details you can share on that trial design? And then just a quick one, any potential milestones from GSK for otilimab that you can remind us of?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks for that question. I'll start out and maybe Dan can provide additional context. I think a number of things have been in play and a lot has changed in the last 18 months. But whether it's through government stimulus or through changing consumer preferences and changing consumer behavior, we've seen a remarkable increase in our deposit balances, and that's across our footprint of both Canadian banking and international banking.
That's led to remarkable consumer liquidity, as we talked about. So those changes in our provisions are very strongly driven by that changing consumer behavior, which has resulted in lower delinquency, lower earning, we see better recovery, which has driven improvement on the provisions basis and business mix. That's been a very, very strong driver in that outcome and ultimately, of course, translating through it on a cash basis to those lower write-offs. So that, we think, is with us for quite some time.
If we look at the excess deposit balances in Canada, they've built up through a mixture of measures over the course of pandemic. And if we see spending go back to pre-COVID levels, the Canadian consumer on our balance sheet has two years of additional liquidity. That gives us a lot of content in our outlook from here. Dan, any additional comments?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. You bet.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I just simply said, Bill, you're thinking about the right way, right? I think that you know, we're very disciplined in that we look at almost every trade. But you really have to step back and look at the overall balance sheet. You know, we're below $7 billion in -- in securities, right? And so at some point, you're really only going to go so low. But if you compare that to when you make that decision and think on average where the tenure has been, not today but where it has been, we're really happy with our -- our decision.
But at the same time, you're totally right, like you got to look at it as a portfolio and we -- and we do believe, and we're getting more and more evidence particularly as new programs come in life and, you know, the infrastructure, Bill, that we're talking about next, right? It gives us some sense that the risk is lowering that, you know, and that the cash may be around a lot -- a lot a little bit longer. So -- so we'll have to look at that -- that overall portfolio and realize how small can the -- can the of securities portfolio get.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Good morning. Just wanted to follow up on clean energy and the growth there. Just curious. What should be the lead time on the bookings turning to growth? Because I would have thought that -- with the bookings being up so much year-over-year for three quarters now, that you'd have organic growth there, but it seems like the organic growth is still negative. So I know you mentioned like COVID-19 impact. I don't know how much of that was driving an organic decline or if it's some of the supply chain stuff, but what should the lead time be in when could that segment turn to organic growth?

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. I think generally, our higher margin piece, Paretosh, are growing faster than the lower margin pieces. So we do have a nice mix phenomenon there. Certainly, electronics, new energy and then auto electronics are three of the areas where we see more fundamental growth that is both organically gaining share as well as underlying markets. So there's a positive mix dynamic long-term.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
That's correct, Kevin.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
John, do you want to handle that?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Dan, why don't just spend a moment just outlining the three or four different types of contracts on your program side that you typically get involved in?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
So Jim, we're actually not hearing a whole lot right now in terms of any significant changes from what's happened here in December. We're going to stay tuned, obviously, it's pretty important but it just tells you the nature of this virus. It seems like sometimes we might have it under control, and then all of a sudden we get these spikes, and it can influence the ability to perform procedures and treat these patients. You know, some of the things that we have heard are that, certain regions of the country tend to be more impacted than others. I guess, like the rest of the world, we're all waiting to see kind of the effect of the vaccinations and how it can help economies recover, and as well as, allow patients to seek treatment and then be in a position to be treated by their physicians in the proper care setting. So we'll be talking more about this, unfortunately, I think as we go through the year.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
This is Michael on for Colby. Two questions, if I may. If I'm not mistaken, last quarter, you said that you expected revenue and gross margins to be flat quarter-over-quarter. In this quarter, we saw a sequential decline.
So my question is, I mean, as it stands, how would you describe your visibility into the business and into your guidance? And then secondly, related to the software downloads, if I'm not mistaken, I believe in 2019, the company backed away from doing software downloads, and I think the reason was because it was unprofitable. Just wondering what's changed in that area and why you're pivoting to pursue that now? Thank you.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
All right. Thanks.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks, Chris.

    Prediction (one of UP, DOWN, SAME): UP